Single Point Partners’s AstraZeneca AZN Stock Holding History

Single Point Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,339	Closed	-$325K	–	76
2023 Q1	$325K	Buy	2,339 +261	+13%	+$35.1K	0.07%	103
2022 Q4	$282K	Buy	+2,078	New	+$261K	0.07%	112
2022 Q3	–	Sell	-1,671	Closed	-$221K	–	131
2022 Q2	$221K	Buy	+1,671	New	+$219K	0.06%	111

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Single Point Partners's AZN Position: Q2 2023 in Review

Single Point Partners sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 2,339 shares — an estimated $325K sold.

Single Point Partners first reported a position in AZN in Q2 2022 and held it in 3 quarters. The position peaked at $325K in Q1 2023. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Single Point Partners reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Single Point Partners sold 2,339 AstraZeneca shares in Q2 2023, an estimated $325K.
Single Point Partners first reported a position in AstraZeneca in Q2 2022 and held it in 3 quarters.
Single Point Partners's AstraZeneca position peaked at $325K in Q1 2023.
1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Single Point Partners's 13F filing for Q2 2023, filed 10 Jul 2023.